Manuel Neves

Manuel Neves

Auto-generated profile, based on publicly available information

Manuel Neves

Experimental Pathology and Therapeutics group, Portuguese Institute for Oncology of Porto, Porto, Portugal

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Drug Resistance Updates
Verified
Journal Article
Closed access
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
APAndreia Peixoto
Andreia Peixoto
MNManuel Neves
Manuel Neves
CGCristiana Gaiteiro
Cristiana Gaiteiro
CRCelso Reis
Celso Reis
Lúcio Lara SantosLúcio Lara Santos
Lúcio Lara Santos

16 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCCéu Costa
Céu Costa
SPSofia Pereira
Sofia Pereira
IPO-Porto LimaIPO-Porto Lima
IPO-Porto Lima
APAndreia Peixoto
Andreia Peixoto
Elisabete FernandesElisabete Fernandes
Elisabete Fernandes
Lúcio Lara SantosLúcio Lara Santos
Lúcio Lara Santos
Muscle invasive bladder cancer (MIBC, stage ≥T2) is generally associated with poor prognosis, constituting the second most common cause of death among genitourinary tumours. Due to high molecular heterogeneity significant variations in the natural history and disease outcome have been observed. This has also delayed the introduction of personalized therapeutics, making advanced stage bladder cancer almost an orphan disease in terms of treatment. Altered protein glycosylation translated by the expression of the sialyl-Tn antigen (STn) and its precursor Tn as well as the activation of the PI3K/Akt/mTOR pathway are cancer-associated events that may hold potential for patient stratification and guided therapy. Therefore, a retrospective design, 96 bladder tumours of different stages (Ta, T1-T4) was screened for STn and phosphorylated forms of Akt (pAkt), mTOR (pmTOR), S6 (pS6) and PTEN, related with the activation of the PI3K/Akt/mTOR pathway. In our series the expression of Tn was residual and was not linked to stage or outcome, while STn was statically higher in MIBC when compared to non-muscle invasive tumours (p = 0.001) and associated decreased cancer-specific survival (log rank p = 0.024). Conversely, PI3K/Akt/mTOR pathway intermediates showed an equal distribution between non-muscle invasive bladder cancer (NMIBC) and MIBC and did not associate with cancer-specif survival (CSS) in any of these groups. However, the overexpression of pAKT, pmTOR and/or pS6 allowed discriminating STn-positive advanced stage bladder tumours facing worst CSS (p = 0.027). Furthermore, multivariate Cox regression analysis revealed that overexpression of PI3K/Akt/mTOR pathway proteins in STn+ MIBC was independently associated with approximately 6-fold risk of death by cancer (p = 0.039). Mice bearing advanced stage chemically-induced bladder tumours mimicking the histological and molecular nature of human tumours were then administrated with mTOR-pathway inhibitor sirolimus (rapamycin). This decreased the number of invasive lesions and, concomitantly, the expression of STn and also pS6, the downstream effector of the PI3K/Akt/mTOR pathway. In conclusion, STn was found to be marker of poor prognosis in bladder cancer and, in combination with PI3K/Akt/mTOR pathway evaluation, holds potential to improve the stratification of stage disease. Animal experiments suggest that mTOR pathway inhibition could be a potential therapeutic approach for this specific subtype of MIBC.

1 September 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
Rita AzevedoRita Azevedo
Rita Azevedo
José Alexandre FerreiraJosé Alexandre Ferreira
José Alexandre Ferreira
APAndreia Peixoto
Andreia Peixoto
MNManuel Neves
Manuel Neves
NSNuno Sousa
Nuno Sousa
Lúcio Lara SantosLúcio Lara Santos
Lúcio Lara Santos